Skip to main content
. 2015 Sep;8(9 Suppl):S4–S26.

TABLE 1.

A summary of new systemic drug therapies for psoriasis

DRUG CURRENT STATUS AND OBSERVATIONS COMMENTS
Certolizumab-Pegol Developed for treating Crohn’s disease
Ustekinumab Antagonizes IL-23 by targeting the p19 subunit (not shared) Pure IL-23 antagonist; adverse events include risk of serious infection
Guselkumab Phase 2 dose-ranging studies resulted in comparisons to adalimumab
Tidrakizumab Phase 2 dose-ranging studied, good PASI-90 scores at 12 weeks. Antagonizes IL-23 by targeting p19 subunit Well-tolerated
Boehringer-Ingelheim 655066 Novel monoclonal antibody, phase 2 proof-ofconcept study with 58% achieving PASI-90 and remaining clear at 66 weeks Subcutaneous injection, may need dosing only every four months
Secukinumab, ixekizumab, and brodalumab IL-17 antagonists Secukinumab approved in U.S. for psoriasis in May 2015